Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some user claims match the provided label excerpts (sections 5.1 and 5.2) only insofar as general safety is concerned, but multiple material claims (indication, approval basis, formulation/ingredient relationship, and sales figures) are not supported by the supplied prescribing-information text.
Category Scores
Accurate Statements
ONIVYDE can cause severe or life-threatening neutropenia and fatal neutropenic sepsis.
Supported by label excerpt Section 5.1 (neutropenia and fatal neutropenic sepsis).
ONIVYDE can cause severe and life-threatening diarrhea.
Supported by label excerpt Section 5.2 (severe/life-threatening diarrhea).
Unsupported Statements
Onivyde (nal-IRI) generated $141 million in net sales in 2023.
Net sales figures are not present in the provided prescribing-information excerpts.
Onivyde (nal-IRI) net sales increased to $141 million in 2023 from $108 million in 2022.
Net sales figures are not present in the provided prescribing-information excerpts.
Onivyde (nal-IRI) net sales were $39 million in the first quarter of 2024.
Net sales figures are not present in the provided prescribing-information excerpts.
Onivyde first-quarter net sales in 2024 ($39 million) were up from $30 million in the same period of 2023.
Net sales figures are not present in the provided prescribing-information excerpts.
Onivyde is indicated for patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
The provided label content does not include the Indications section.
Onivyde's approval is based on clinical trials demonstrating its benefit in patients with advanced pancreatic cancer who have progressed on gemcitabine.
The provided label excerpts do not include the clinical studies/approval-basis content.
Onivyde is a liposomal encapsulation formulation of irinotecan.
The provided label excerpt includes 'irinotecan liposome injection', but the explicit statement that it is 'liposomal encapsulation formulation of irinotecan' is not directly corroborated beyond the dosage form heading.
The liposomal encapsulation of irinotecan alters its pharmacokinetic profile and delivery.
No pharmacokinetic/delivery statements are included in the provided label excerpts.
Irinotecan is a topoisomerase I inhibitor.
Mechanism-of-action is not included in the provided label excerpts.
Contradictions
Important Omissions
If evaluating medication safety claims, the response text provided did not include the specific label-directed management details (e.g., withholding/resume thresholds for ANC/neutropenic fever; 'Do not administer' for bowel obstruction; atropine/loperamide guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because multiple material claims (indication, approval basis, mechanism/formulation implications) are not supported by the provided label excerpts, reliance on them could misrepresent on-label use. Safety warning-related claims about neutropenia and diarrhea are directionally consistent with the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Material claims about indication/approval basis/mechanism and all net sales figures are not supported by the supplied prescribing-information excerpts.
Suggested Improvement
Limit assertions to information explicitly present in the provided label text (Sections 5.1 and 5.2), and omit or cite label sections for Indications, Clinical Studies, Pharmacodynamics/PK, and formulation description beyond what is shown.